Merit Medical Systems

Director Lynne N. Ward executed an open-market sale of 5,000 Merit Medical Systems shares on May 7 for about $313,000, cutting her direct holdings from 12,809 to 7,809 shares. The sale occurred amid a share decline to a 52-week low and investor concerns about macroeconomic headwinds, higher tariffs and decelerating revenue growth. Ward's remaining position suggests the disposition may have been personal rather than a full loss of confidence in the company. » Mere på finance.yahoo.com

Merit Medical Systems shares fell to a new 52-week low of $60.50, losing 7.09% last week and down about 34.7% year-to-date. Ten analysts have cut their earnings estimates despite the company having a Piotroski score of 9. Merit reported better-than-expected results for Q1 2026 and slightly raised its revenue outlook, while analysts adjusted price targets differently (Needham $90, BofA $80). » Mere på de.investing.com

Merit Medical reported Q1 2026 EPS of $0.86 (expectation $0.83) and revenue of $381.9 million (expectation $377.81 million), representing 7% year-over-year revenue growth. The non-GAAP operating margin was 19.7%, the highest first-quarter level in company history. The stock rose 5.24% after hours. For the next fiscal year the company expects EPS between $0.98 and $1.17 but cites risks from tariffs, OEM inventory drawdowns and geopolitical tensions. » Mere på de.investing.com

The stock of Merit Medical Systems fell to a 52-week low of $66.33, well below this year’s high of $100.19; over 12 months the stock lost 29.92%. Eight analysts recently lowered their earnings estimates, yet the company shows strong financial health and a P/E ratio of 31.18 according to the data. Quarterly results are due in two days; analysts’ price targets range from $78 to $122. Merit also reported the acquisition of View Point Medical for $140 million and an exclusive distribution agreement with Medtronic for the ViaVerte system, prompting analysts to update their targets differently. » Mere på de.investing.com

Merit Medical is acquiring View Point Medical as a 100% subsidiary in a transaction with a total value of approximately $140 million. Merit paid $90 million in cash at closing; two additional payments of $25 million each will follow on the first two anniversaries. The acquisition expands Merit’s therapeutic oncology portfolio through the FDA‑cleared OneMark Detection Imaging System and is expected to contribute about $2–4 million in revenue in 2026, rising to $14–16 million in 2027. For 2026, Merit expects non‑GAAP earnings dilution of roughly $0.05 per share, but the acquisition is expected to be accretive over the long term; Piper Sandler advised financially and Baker & McKenzie provided legal counsel. » Mere på de.investing.com